Codon 72 and G13964C intron 6 polymorphisms of TP53 in relation to development and progression of breast cancer in India

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 8, 2011, Pages 1893-1898

  Surekha, D ^a,b   Sailaja, K ^a   Nageswara Rao, D ^a   Padma, T ^a   Raghunadharao, D ^c   Vishnupriya, S ^a  

^a OSMANIA UNIVERSITY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Breast cancer; Polymorphisms; Receptor status; TP53 codon 72; TP53 intron 6 (G13964C)

Indexed keywords

EID: 84858110865     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bergman-Jungestrom M, Gentile M, Lundin AC, et al (1999). Anita K, Robert WP, Eduardo LF (2004). P53 codon 72 polymorphism and cervical neoplasia: A meta-analysis review. Cancer Epidemiol Biomarkers Prev, 13, 11-22.
2. Anna Marsh, Amada Spurdle B, Bruce Turner C, et al (2001). The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Res, 3, 346-9.
3. Avigad S, Barel D, Blau O, et al (1997). A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene, 14, 1541-5.
4. Bergamaschi D, Samuels Y, Sullivan A, et al (2006). Iaspp preferentially binds p53 proline -rich region and modulates apoptosis function of codon 72 polymorphic p53. Nat Genet, 38, 1133-41.
5. Bonafe M, Ceccarelli C, Farabegoli F (2003). Retention of the p53 codon 72 arginine allele is associated with a reduction of disease -free and overall survival in arg/pro heterozygous breast cancer patients. Clin Cancer Res, 9, 4860-4.
6. Buller RE, Skilling JS, Kaliszewski S, et al (1995). Absence of significant germline p53 mutations in ovarian cancer patients. Gynecol Oncol, 58, 368-374.
7. Dumont P, Leu JI, Della Pietra AC, et al (2003). The codon 72 polymorphism variants of p53 have markedly different apoptotic potential. Nat Genet, 33, 357-65.
8. Fiszer-Maliszewska L, Bernarde Kazaowska, Piotr Kusnierczyk, et al (2003). Is P53 intronic variant G13964C associated with predisposition to cancer? J Appl Genet, 44, 547-52.
9. Goessl C, Plaschke J, Pistrius S, et al (1997). An intronic germline transition in the HNPCC GENE Hmsh2 is associated with sporadic colorectal cancer. Eur J Cancer, 33, 1869-74.
10. Gottlieb TM, Oren M (1996). P53 in growth control and neoplasia. Biochim Biophys Acta, 1287, 77-102.
11. Greenblastt MS, Bennett WP, Hollestein M, et al (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular phathogenesis. Cancer Res, 54, 4855-4878.
12. Huang XE, Hamajima N, Katsuda N, et al (2003). Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphism with the risk of Japanese breast cancer. Breast Cancer, 10, 307-11.
13. Kunzang C, Anupama A, Annapurna R, et al (2002). Study of p53 codon 72 polymorphism in various ethnic groups of North India. Current Science, 82, 10.
14. Langerod A, Bukholm IR, Lonning PE, et al (2002). The TP73 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomark Prev, 11, 1684-8.
15. Laurie CC, Stan LF (1994). The effect of an intronic polymorphism on alcohol dehydrogenase expression in Drosophila Melanogaster. Genetics, 138, 379-85.
16. Lehman TA, Haffty BG, Carbone CJ, et al (2000). Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res, 60, 1062-9.
17. Liu X, Sinn-H-P, Ulmer HU, et al (2004). Intronic TP53 germline sequence variants modify the risk in German breast/ovarian cancer families. Hered Cancer Clin Pract, 2, 139-45.
18. Mabrouk I, Baccouche S, EL-Abed R, et al (2003). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann NY Acad Sci, 1010, 764-70.
19. March A, Spurdle AB, Turner BC, et al (2001).The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Res, 3, 346-9.
20. McDaniel T, Carbone D, Takahashi T (1991). The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res, 19, 4796.
21. Noma C, Miyashi T, Taguchi T, (2004). Association of p53 genetic polymorphism (Arp 72 Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett, 210, 197-203.
22. Nur Buyru, Hatice Tigli, Nejat Dalay (2003). P53 codon 72 polymorphism in breast cancer. Oncology Rep, 10, 711-4.
23. Nuremberg, Lahari, (1991). A rapid non-enzymatic method for the preparation of HMW from blood RFLP studies. Nucleic Acid Research, 19, 5444.
24. Ohayon T, Gershoni-Baruch R, Papa MZ, et al (2005). The R72P p53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer, 92, 1144-8.
25. Papadakis ED, Soulitzis N, Spandidos DD (2002). Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer, 87, 1013-8.
26. Peller S, Kopilova Y, Slutzki S, et al (1995). A novel polymorphism in intron 6 of the human p53 gene:a possible association with cancer predisposition and susceptibility. DNA Cell Biol, 14, 983-90.
27. Siddique M, Sabapathy K (2006). Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene, 25, 3489-500.
28. Storey A, Thomas M, Kalita A, et al (1998). Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature, 393, 229-34.
29. Suspitsin EN, Buslov KG, Grigoriev MY, et al (2003). Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer, 103, 431-3.
30. Thomas M, Kalita A, Labrecque S, et al (1999).Two polymorphic variants of wild type p53 differ biochemical and biologically. Mol Cell Biol, 19, 1092-110.
31. van Heemst D, Moonijaert SP, Beelman M, et al (2005). Variation in human TP53 gene effects old age survival and cancer mortality. Exp Gerontol, 40, 11-5.
32. Varley JM, McGown G, Thorncroft M, et al (2001). Significance of intron 6 sequence variations in the TP53 gene in Li-Fraumeni syndrome. Cancer Genet Cytogenet, 29, 85-7.
33. Weston A, Pan CF, Ksieski HB, et al (1997). P53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev, 6, 105-12.